No Data
Hong Kong stocks movement | ASCLETIS-B (01672) rose over 8% in early trading, with positive interim results reported from the Phase Ib trial of the obesity drug ASC30 in the USA.
ASCLETIS-B (01672) rose over 8% in early trading, as of this writing, it is up 4.58%, quoted at HKD 8.45, with a trading volume of HKD 16.3974 million.
Express News | Ascletis Pharma Inc - Asc30 Sq Injection Shows 36-Day Half-Life in Obesity Patients
Express News | Ascletis Pharma: Announces Positive Interim Results From Its U.S. Phase Ib Trial With Asc30
ASCLETIS-B (01672): Expected to become the first-in-class subcutaneous small molecule GLP-1R agonist ASC30 in the USA, with positive mid-term results from the Phase Ib trial.
ASCLETIS-B (01672) announced that it is conducting a randomized, double-blind, placebo-controlled trial of ASC3 in the USA...
Ascletis Pharma's Attributable Loss Widens in 2024 as Revenue Plummets
ASCLETIS-B (01672.HK) announced its annual performance, with R&D expenses increasing by 39.5% to approximately 0.302 billion yuan.
Glory Securities announced on March 26 that ASCLETIS-B (01672.HK) reported for the year ending December 31, 2024, that the group's R&D expenses increased by 39.5% from the previous year, approximately reaching RMB 302.4 million from about RMB 216.8 million. The group's annual loss increased from RMB 144.7 million in the previous year to RMB 300.9 million, primarily due to increased R&D expenditures related to obesity and other metabolic diseases. The group has ample funds to support its innovative R&D over the next five years. During the reporting period and up to the date of this announcement, the group has...
